|

CD19-BCMA CAR-T cells infusion Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing GoBroad Hospital1

Indications

  • Primary Sjogren's Syndrome Combined With Pulmonary Hypertension1
  • Refractory Lupus Nephritis1
  • Systemic Sclerosis1
  • Lupus1

Other1 trial

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.